Lilly Articles
Stock Commentary - New York
6 June 2005
Lilly's Cymbalta: strong performance in elderly
6 June 2005
FDA assesses ED drug link to blindness
6 June 2005
Strattera: emotional benefit in women
6 June 2005
Eli Lilly's olanzapine: better compliance
6 June 2005
Positive results for AstraZeneca's Seroquel
30 May 2005
ICOS' 1st-qtr share losses narrow to $0.73
23 May 2005
Amylin EPS loss inches up 7.5% to $0.43
16 May 2005
Stock Commentary - New York
9 May 2005
Eli Lilly/Amylin's diabetes drug gets FDA OK
9 May 2005
Japan stock market week to May 2
9 May 2005
EMEA warning over SSRIs, SNRIs in children
26 April 2005
Stock Commentary - New York
25 April 2005
Corcept's Corlux shows good weight loss result
25 April 2005
Genasense shows strong combination performance
25 April 2005
Stock Commentary - Europe
25 April 2005
Eli Lilly reports 84% income rise in 1st qtr
25 April 2005
US court upholds Lilly's Zyprexa patent
25 April 2005
Rising tide of litigation against pharma from govt, states and whistleblowers, FDLI told
25 April 2005
Lilly pledges $12.5M to speed cancer clinical research
18 April 2005
Ligand buys down Ontak royalties
18 April 2005
BI/Eli Lilly's Yentreve effective in SUI
18 April 2005
Japan's most-admired pharma companies: NPP survey
18 April 2005
UK guide for industry on Rx access in DCs
4 April 2005
Stock Commentary - New York
28 March 2005
Spanish pharma seeks govt aid over R&D costs
28 March 2005
Bulgaria's Commercial League expanding
28 March 2005
Polish pharma market set for recovery
21 March 2005
Greek pharma losing private market share
21 March 2005
Greek pharma losing private market share
21 March 2005
Polish pharma market set for recovery
21 March 2005
Scotland OKs Femara, rejects other drugs
14 March 2005
Italy OKs 79 new drugs, plans R&D promotion
7 March 2005
New US ethnic pharma marketing research
28 February 2005
Drugs from Europe "safer than getting them in the USA," Pfizer VP tells US Senate hearing
28 February 2005
Positive opinion for Lilly's Cymbalta
28 February 2005
2004 "best-year in history" at Merck KGaA
21 February 2005
US volume Rx sales rise 8.3% in 2004
21 February 2005
Microdosing trial produces good result
21 February 2005
Shionogi's 3rd-qtr sees sales drop 2.9%
21 February 2005
Alkermes cuts 3rd-qtr loss
14 February 2005
SCOLR secures raloxifene-making contract
14 February 2005
Stock Commentary - New York
14 February 2005
Albany Molecular renews alliance with Lilly
14 February 2005
Australia backtracks on 12.5% generic price cut
14 February 2005
BioImage licenses Redistribution to Boeh Ingelheim
14 February 2005
Editor's views on US profit repatriation, re-importation
7 February 2005
Novo Nordisk US appointments
7 February 2005
Tougher pharma patent laws bringing multinationals back to India
7 February 2005
BMJ apologizes to Lilly
31 January 2005
Sirna discusses R&D pipeline
31 January 2005
New product launches in 2004
31 January 2005
Cialis joins BASS as premier sponsor
31 January 2005
Poor year for MNCs in Poland
31 January 2005
Stock Commentary - New York
24 January 2005
Highlights of pharmaceutical mergers and acquisitions in 2004
24 January 2005
Lilly, J&J plan profits repatriation
24 January 2005
Lilly launches corrective outreach program for Prozac
17 January 2005
Ligand to buy down Lilly Ontak royalties
17 January 2005
Stock Commentary - New York
10 January 2005
EC OKs Cymbalta for major depression
10 January 2005
BMJ turns over confidential documents to FDA on Lilly's Prozac
10 January 2005
Lilly adds liver warning to Strattera label
10 January 2005
Pharmaceutical firms are conducting trials oversees
20 December 2004
FDA OKs Ranbaxy's generic Prozac
20 December 2004
Benefits of long-term Zyprexa therapy
20 December 2004
Stock Commentary - New York
13 December 2004
Cubist/Chiron's Cubicin filed in EU
13 December 2004
Lack of candidate drugs constraining bladder cancer Rx mkt
13 December 2004
Barr confirms challenge to Zyprexa patent
13 December 2004
Lilly ICOS celebrates a "promising" first year of Cialis in the USA
13 December 2004
Gemzar combination with Taxol OKed in UK
13 December 2004
Isis/Lilly's LY2181308 advances to clinic
22 November 2004
Quintiles' 3rd-qtr revenues rise 9%
22 November 2004
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
